The first p2b abstract is hot off the press

and shows encouraging Phase 2b data in a tough knee OA population: 225 patients with moderate–severe pain and nociplastic features (PainDETECT ≥13) randomized to APPA 800/1200 mg BID vs placebo for 12 weeks.

The data indicates dose-dependent efficacy signals on key outcomes – and a pre-planned subgroup – with clinically relevant, statistically significant benefits of APPA at 1200 mg across multiple measures, and demonstrating a very good safety and tolerability profile.

The OARSI 2026 Late Breaking Abstract “Evaluation of Efficacy and Safety of a fixed-dose combination of apocynin and paeonol in knee OA patients with moderate to severe pain and nociplastic pain features: a phase 2b trial” was authored by Bihlet AR1, Petersen, N1, Kaaber AB1, Petersen EE1, Rovsing H2, Alexandersen P3, Larsen SS4, Ming-Chu Lau E5, Miles D6, Larkins N6, Reynolds A6, Conaghan PC7.

The trial was sponsored by AKL Therapeutics Ltd and performed by NBCD, the Sanos Clinics and Dr. Edith Lau in Hong Kong. Please contact us for a copy of the abstract and/or poster.

1 NBCD A/S, Søborg, Denmark
2 Sanos Clinic Northern Jutland, Gandrup, Denmark
3 Sanos Clinic Southern Denmark, Vejle, Denmark
4 Sanos Clinic Capital, Herlev, Denmark
5 Center for Clinical Research, Hong Kong
6 AKL Therapeutics, Stevenage, United Kingdom
7 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom